ArticleResearch in pharmaceutical sciences2025
Protective effects of curcumin/magnesium oxide nanoparticles on ketamine-induced neurotoxicity in the mouse hippocampus.
Article in Research in pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Nanotechnology can improve drug delivery by enhancing cell selectivity, releasing at specific target sites, and improving bioavailability while reducing adverse events and potential treatment costs. The current study aimed to synthesize curcumin/magnesium oxide (Cur/MgO) nanoparticles (NPs) and evaluate their neuroprotective effects in a mouse model of ketamine-induced neurotoxicity. Experimental approach: XRD, FE-SEM, and a particle size analyzer determined the average crystalline and particle sizes. UV-Vis examined absorption patterns, and FT-IR spectroscopy analyzed the functional groups involved in the reaction. To evaluate the effectiveness of Cur/MgO NPs on ketamine-induced neurotoxicity, male BALB/c mice were divided into 7 groups and received the following treatments (intraperitoneally, daily for 2 weeks). Groups 1 and 2 received normal saline (0.2 mL) and ketamine (25 mg/kg). Group 3 received curcumin (40 mg/kg) and ketamine (25 mg/kg). Groups 4-6 received ketamine (25 mg/kg) and Cur/MgO NPs (10, 20, and 40 mg/kg). Group 7 received MgO (5 mg/kg) and ketamine (25 mg/kg). Finally, the hippocampal tissues were examined morphologically and analyzed for oxidative stress, inflammation, apoptotic markers, and mitochondrial quadruple complex enzymes. Results/Findings: Both Cur/MgO NPs and curcumin reduced IL-1β, TNF-α, Bax, and MDA levels and GSSG content and increased GSH, Bcl-2, GPx, GR, and SOD. Cur/MgO NPs and curcumin also increased mitochondrial quadruple complex enzymes and inhibited histological changes in the dentate gyrus and CA1 hippocampus areas in ketamine-induced neurotoxicity. Conclusion and implications: Cur/MgO NPs were more neuroprotective against the ketamine-induced histomorphological changes, inflammation, apoptosis, and oxidative stress than curcumin alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.